EXPLORING THE TREATMENT MODALITIES FOR CUTANEOUS MELANOMA; A NETWORK META- ANALYSIS
Authors:
Chrysostomidis A., Louizakis A., Michailidou D., Grivas T. , Pasteli N.*, Boukovinas I.**, Kyrgidis A., Vahtsevanos K.
Affiliation:
1 Oral Maxillofacial Surgery Department, G Papanikolaou Hospital, Aristotle University, Thessaloniki, Greece
*Pathology department, G Papanikolaou Hospital, Aristotle University, Thessaloniki, Greece
**Medical Oncologist, private practice, Thessaloniki, Greece
Doi: 10.54936/haoms242p53
ABSTRACT:
Objective: This Bayesian network meta-analysis aimed to determine the most effective therapeutic option for cutaneous melanoma.
Materials and Methods: A systematic search was conducted in PubMed, Embase, Cochrane Library, and the American Society of Clinical Oncology databases from inception until August 20th, 2018. Among 872 identified records, six met the inclusion criteria and were included in the meta-analysis. A total of 4,244 patients from six randomized studies were included. Adjusted hazard ratios (HRs) for Recurrence Free Survival (RFS), Overall Survival (OS), and relative odds ratios (ORs) for adverse events (AEs) were calculated. Surface under the cumulative ranking (SUCRA) probabilities were computed after data visualization. The therapies considered in the selected studies were combined dabrafenib and trametinib, vemurafenib, nivolumab, ipilimumab, and pembrolizumab.
Results: Nivolumab had the highest probability (75.1%) of being the most effective in terms of RFS, followed by dabrafenib+trametinib, pembrolizumab, ipilimumab, and vemurafenib. However, OS could not be estimated. Regarding AEs, pembrolizumab and nivolumab showed the highest probability of being associated with fewer and less severe AEs (83.1% and 64.4% respectively).
Conclusions: In conclusion, the effectiveness of new drugs in the adjuvant therapy of cutaneous melanoma is noteworthy. However, individualized therapy remains the optimal choice.
KEY WORDS:
Authors:
Chrysostomidis A., Louizakis A., Michailidou D., Grivas T. , Pasteli N.*, Boukovinas I.**, Kyrgidis A., Vahtsevanos K.
Affiliation:
1 Oral Maxillofacial Surgery Department, G Papanikolaou Hospital, Aristotle University, Thessaloniki, Greece
*Pathology department, G Papanikolaou Hospital, Aristotle University, Thessaloniki, Greece
**Medical Oncologist, private practice, Thessaloniki, Greece
Doi: 10.54936/haoms242p53
ABSTRACT:
Objective: This Bayesian network meta-analysis aimed to determine the most effective therapeutic option for cutaneous melanoma.
Materials and Methods: A systematic search was conducted in PubMed, Embase, Cochrane Library, and the American Society of Clinical Oncology databases from inception until August 20th, 2018. Among 872 identified records, six met the inclusion criteria and were included in the meta-analysis. A total of 4,244 patients from six randomized studies were included. Adjusted hazard ratios (HRs) for Recurrence Free Survival (RFS), Overall Survival (OS), and relative odds ratios (ORs) for adverse events (AEs) were calculated. Surface under the cumulative ranking (SUCRA) probabilities were computed after data visualization. The therapies considered in the selected studies were combined dabrafenib and trametinib, vemurafenib, nivolumab, ipilimumab, and pembrolizumab.
Results: Nivolumab had the highest probability (75.1%) of being the most effective in terms of RFS, followed by dabrafenib+trametinib, pembrolizumab, ipilimumab, and vemurafenib. However, OS could not be estimated. Regarding AEs, pembrolizumab and nivolumab showed the highest probability of being associated with fewer and less severe AEs (83.1% and 64.4% respectively).
Conclusions: In conclusion, the effectiveness of new drugs in the adjuvant therapy of cutaneous melanoma is noteworthy. However, individualized therapy remains the optimal choice.
KEY WORDS: